UK’s NICE Unveils New 5-Year Strategy to Accelerate Patient Access
The UK’s National Institute for Health and Care Excellence (NICE) has released a new five-year plan to accelerate patient access to new treatments as it moves forward independently of the EU’s regulatory authority now that the UK has fully separated from the bloc.
In its strategy document spanning 2021 to 2026, NICE said it will emerge from the pandemic with a renewed determination to reduce inequities in healthcare and that it will work “to reduce bureaucracy and to speed up access to the latest and most effective treatments.”
The plan features four main commitments: rapid evaluations of new treatments; regular updates of guidelines; working with stakeholders to increase the implementation of guidance; and monitoring health outcomes using real-world data.
In January, the UK launched an accelerated drug approval mechanism, the Innovative Licensing and Access Pathway that involves multiple government entities, including NICE.